PreCision Dermatology Report issue

For profit Phase 2
Founded: New York NY United States (2010)
Status: Acquired by Bausch Health Companies (2014)

Organization Overview

First Clinical Trial
2013
NCT01826461
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PRECISION DERMAT | PreCision Dermatology, Inc.

Active Ingredients

Marketed Drugs (3)

Key: PreCision Dermatology (2) Acquired (1)

clindamycin (cleocin) (2000)

hydrocortisone (solu-cortef) (1982)

minocycline (minocin) (1972)

Drugs in Phase 2 Trials (4)

Key: PreCision Dermatology (2) Acquired (2)

edetic acid (1 trial)

minocycline (minocin) (2 trials)

pdi-192 (1 trial)

pdi-320 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Rosacea (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4